Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Curex vs AgelessRx

Both scored on the same six-factor Match Score. Curex wins this matchup with a 86 to 83 edge.

Higher Match Score

Curex

#8 · Grade B+

People who value a transparent, well-supported program with simple same-price-either-molecule billing.

Visit Curex
VS

AgelessRx

#16 · Grade B

Budget-conscious patients who also value a longevity-medicine framing and some brand access.

Visit AgelessRx

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
80
88
Speed to Start
88
80
Formulary Match
86
84
Support Level
88
84
Flexibility
86
86
Transparency
88
78

Price, coverage & formulary

DetailCurexAgelessRx
Semaglutide$199/mo$139/mo
Tirzepatide$199/moNot disclosed
CoverageAll 50 statesNot disclosed
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjectable only
Match Score86 · B+83 · B
Winner: Curex

Curex edges out AgelessRx, 86 to 83 on the default Match Score. A high-disclosure program with identical flat pricing on both molecules, an oral route, and hands-on support.

AgelessRx is still a fair pick if its strengths line up with yours — best for: Budget-conscious patients who also value a longevity-medicine framing and some brand access.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Curex reviewFull AgelessRx review

More head-to-heads

Or browse alternatives to Curex and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.